Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
Short-term probabilistic forecasts of the trajectory of the COVID-19 pandemic in the United States have served as a visible and important communication channel between the scientific modeling community and both the general public and decision-makers. Forecasting models provide specific, quantitative, and evaluable predictions that inform short-term decisions such as healthcare staffing needs, school closures, and allocation of medical supplies. Starting in April 2020, the US COVID-19 Forecast Hub (https://covid19forecasthub.org/) collected, disseminated, and synthesized tens of millions of specific predictions from more than 90 different academic, industry, and independent research groups. A multi-model ensemble forecast that combined predictions from dozens of different research groups every week provided the most consistently accurate probabilistic forecasts of incident deaths due to COVID-19 at the state and national level from April 2020 through October 2021. The performance of 27 individual models that submitted complete forecasts of COVID-19 deaths consistently throughout this year showed high variability in forecast skill across time, geospatial units, and forecast horizons. Two-thirds of the models evaluated showed better accuracy than a naïve baseline model. Forecast accuracy degraded as models made predictions further into the future, with probabilistic error at a 20-week horizon 3-5 times larger than when predicting at a 1-week horizon. This project underscores the role that collaboration and active coordination between governmental public health agencies, academic modeling teams, and industry partners can play in developing modern modeling capabilities to support local, state, and federal response to outbreaks.
Significance Statement This paper compares the probabilistic accuracy of short-term forecasts of reported deaths due to COVID-19 during the first year and a half of the pandemic in the US. Results show high variation in accuracy between and within stand-alone models, and more consistent accuracy from an ensemble model that combined forecasts from all eligible models. This demonstrates that an ensemble model provided a reliable and comparatively accurate means of forecasting deaths during the COVID-19 pandemic that exceeded the performance of all of the models that contributed to it. This work strengthens the evidence base for synthesizing multiple models to support public health action.
Competing Interest Statement
AV, MC, and APP report grants from Metabiota Inc outside the submitted work.
Funding Statement
For teams that reported receiving funding for their work, we report the sources and disclosures below. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies. CMU-TimeSeries: CDC Center of Excellence, gifts from Google and Facebook. CU-select: NSF DMS-2027369 and a gift from the Morris-Singer Foundation. COVIDhub: US CDC (1U01IP001122); NIGMS (R35GM119582). Helmholtz Foundation (SIMCARD Information & Data Science Pilot Project). Klaus Tschira Foundation. Columbia_UNC-SurvCon: GM124104 DDS-NBDS: NSF III-1812699. EPIFORECASTS-ENSEMBLE1: Wellcome Trust (210758/Z/18/Z) GT_CHHS-COVID19: William W. George Endowment, Virginia C. and Joseph C. Mello Endowments, NSF DGE-1650044, NSF MRI 1828187, CDC and CSTE NU38OT000297, PACE at GATech. Andrea Laliberte, Joseph C. Mello, Richard (Rick) E. & Charlene Zalesky, and Claudia & Paul Raines. GT-DeepCOVID: CDC MInD-Healthcare U01CK000531-Supplement. NSF (Expeditions CCF-1918770, CAREER IIS-2028586, RAPID IIS-2027862, Medium IIS-1955883, NRT DGE-1545362), CDC MInD program, ORNL and funds/computing resources from Georgia Tech and GTRI. IHME: The Bill & Melinda Gates Foundation; the state of Washington and NSF (FAIN: 2031096). IowaStateLW-STEM: Iowa State University Plant Sciences Institute Scholars Program, NSF DMS-1916204, NSF CCF-1934884, Laurence H. Baker Center for Bioinformatics and Biological Statistics. JHU CSSE: NSF RAPID (2108526, 2028604) JHU_IDD-CovidSP: State of California, US HHS, US DHS, US Office of Foreign Disaster Assistance, Johns Hopkins Health System, Office of the Dean JHBSPH, Johns Hopkins University Modeling and Policy Hub, CDC (5U01CK000538-03), University of Utah Immunology, Inflammation, & Infectious Disease Initiative (26798 Seed Grant). LANL-GrowthRate: LANL LDRD 20200700ER. MOBS-GLEAM_COVID: COVID Supplement CDC-HHS-6U01IP001137-01; CSTE Cooperative Agreement no. NU38OT000297. NotreDame-mobility and NotreDame-FRED: NSF RAPID DEB 2027718 PSI-DRAFT: NSF RAPID Grant # 2031536. UA-EpiCovDA: NSF RAPID DMS 2028401. UCSB-ACTS: NSF RAPID IIS 2029626. UCSD-NEU: Google Faculty Award, DARPA W31P4Q-21-C-0014, COVID Supplement CDC-HHS-6U01IP001137-01. UMass-MechBayes: NIGMS R35GM119582, NSF 1749854. UMich-RidgeTfReg: UMich Physics Department and Office of Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UMass-Amherst IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
*** The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
This preprint has been revised to include a longer evaluation period for submitting models. It is also more condensed with parts of the manuscript moved to a supplemental analysis. This version contains an additional post hoc analysis of model performance during waves of the pandemic.
Data Availability
All data and code referred to in the manuscript are publicly available.
https://github.com/reichlab/covid19-forecast-hub/
https://github.com/reichlab/covidEnsembles
https://zoltardata.com/project/44
https://github.com/reichlab/covid19-forecast-evals/blob/main/figures/data_revisions.pdf
Subject Area
- Addiction Medicine (343)
- Allergy and Immunology (666)
- Anesthesia (180)
- Cardiovascular Medicine (2629)
- Dermatology (222)
- Emergency Medicine (397)
- Epidemiology (12180)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4069)
- Geriatric Medicine (387)
- Health Economics (678)
- Health Informatics (2627)
- Health Policy (998)
- Hematology (361)
- HIV/AIDS (845)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (431)
- Neurology (3839)
- Nursing (209)
- Nutrition (571)
- Oncology (2011)
- Ophthalmology (582)
- Orthopedics (239)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (74)
- Pathology (471)
- Pediatrics (1109)
- Primary Care Research (448)
- Public and Global Health (6502)
- Radiology and Imaging (1390)
- Respiratory Medicine (869)
- Rheumatology (401)
- Sports Medicine (341)
- Surgery (441)
- Toxicology (52)
- Transplantation (185)
- Urology (165)